Lushun Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Lushun Wang has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Han Xiao
Department of Chemistry, Rice University, Houston, USA
4 shared publications - Axel Loredo
Department of Chemistry, Rice University, 6100 Main Street, Houston, Texas, 77005, USA
3 shared publications - Debopam Chakrabarti
Division of Molecular Microbiology, Burnett School of Biomedical Sciences, University of Central Florida, Orlando, FL 32826, USA
2 shared publications - Elizabeth A. Winzeler
Department of Pediatrics, University of California, San Diego, School of Medicine, La Jolla, CA, USA
2 shared publications Jinhua Wang
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02215, United States
2 shared publications- Monica J. Bohmer
Division of Molecular Microbiology, Burnett School of Biomedical Sciences, University of Central Florida, Orlando, Florida 32826, United States
2 shared publications
Latest Publications
- 12 January 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (2) , 1460-1480
Discovery of Potent Antimalarial Type II Kinase Inhibitors with Selectivity over Human Kinases
While progress has been made in the effort to eradicate malaria, the disease remains a significant threat to global health. Acquired resistance to frontline treatments is emerging in Africa, urging a need for the development of novel antimalarial agents. Repurposing human kinase inhibitors provides a potential expedited route given the availability of a diverse array of kinase-targeting drugs that are approved or in clinical trials. Phenotypic screening of a library of type II human kinase inhibitors identified compound 1 as a lead antimalarial, which was initially developed to target human ephrin type A receptor 2 (EphA2). Here, we report a structure-activity relationship study and lead optimization of compound 1, which led to compound 33, with improved antimalarial activity and selectivity.
- 12 January 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (2) , 1460-1480
Discovery of Potent Antimalarial Type II Kinase Inhibitors with Selectivity over Human Kinases
While progress has been made in the effort to eradicate malaria, the disease remains a significant threat to global health. Acquired resistance to frontline treatments is emerging in Africa, urging a need for the development of novel antimalarial agents. Repurposing human kinase inhibitors provides a potential expedited route given the availability of a diverse array of kinase-targeting drugs that are approved or in clinical trials. Phenotypic screening of a library of type II human kinase inhibitors identified compound 1 as a lead antimalarial, which was initially developed to target human ephrin type A receptor 2 (EphA2). Here, we report a structure-activity relationship study and lead optimization of compound 1, which led to compound 33, with improved antimalarial activity and selectivity.
- 7 June 2023
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 91, 129365
Visible light-activated prodrug system with a novel heavy-atom-free photosensitizer
- 7 June 2023
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 91, 129365
Visible light-activated prodrug system with a novel heavy-atom-free photosensitizer
- 15 March 2023
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 9 (4) , 1004-1021
Human Polo-like Kinase Inhibitors as Antiplasmodials
Protein kinases have proven to be a very productive class of therapeutic targets, and over 90 inhibitors are currently in clinical use primarily for the treatment of cancer. Repurposing these inhibitors as antimalarials could provide an accelerated path to drug development. In this study, we identified BI-2536, a known potent human polo-like kinase 1 inhibitor, with low nanomolar antiplasmodial activity. Screening of additional PLK1 inhibitors revealed further antiplasmodial candidates despite the lack of an obvious orthologue of PLKs in Plasmodium. A subset of these inhibitors was profiled for their in vitro killing profile, and commonalities between the killing rate and inhibition of nuclear replication were noted. A kinase panel screen identified PfNEK3 as a shared target of these PLK1 inhibitors; however, phosphoproteome analysis confirmed distinct signaling pathways were disrupted by two structurally distinct inhibitors, suggesting PfNEK3 may not be the sole target. Genomic analysis of BI-2536-resistant parasites revealed mutations in genes associated with the starvation-induced stress response, suggesting BI-2536 may also inhibit an aminoacyl-tRNA synthetase.
- 15 March 2023
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 9 (4) , 1004-1021
Human Polo-like Kinase Inhibitors as Antiplasmodials
Protein kinases have proven to be a very productive class of therapeutic targets, and over 90 inhibitors are currently in clinical use primarily for the treatment of cancer. Repurposing these inhibitors as antimalarials could provide an accelerated path to drug development. In this study, we identified BI-2536, a known potent human polo-like kinase 1 inhibitor, with low nanomolar antiplasmodial activity. Screening of additional PLK1 inhibitors revealed further antiplasmodial candidates despite the lack of an obvious orthologue of PLKs in Plasmodium. A subset of these inhibitors was profiled for their in vitro killing profile, and commonalities between the killing rate and inhibition of nuclear replication were noted. A kinase panel screen identified PfNEK3 as a shared target of these PLK1 inhibitors; however, phosphoproteome analysis confirmed distinct signaling pathways were disrupted by two structurally distinct inhibitors, suggesting PfNEK3 may not be the sole target. Genomic analysis of BI-2536-resistant parasites revealed mutations in genes associated with the starvation-induced stress response, suggesting BI-2536 may also inhibit an aminoacyl-tRNA synthetase.
- 13 December 2022
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 144 (51) , 23668-23676
Photostable Small-Molecule NIR-II Fluorescent Scaffolds that Cross the Blood–Brain Barrier for Noninvasive Brain Imaging
The second near-infrared (NIR-II, 1000–1700 nm) fluorescent probes have significant advantages over visible or NIR-I (600–900 nm) imaging for both depth of penetration and level of resolution. Since the blood-brain barrier (BBB) prevents most molecules from entering the central nervous system, NIR-II dyes with large molecular frameworks have limited applications for brain imaging. In this work, we developed a series of boron difluoride (BF2) formazanate NIR-II dyes which had tunable photophysical properties, ultrahigh photostability, excellent biological stability, and strong brightness. Modulation of the aniline moiety of BF2 formazanate dyes significantly enhances their abilities to cross the BBB for noninvasive brain imaging. Furthermore, the intact mouse brain imaging and dynamic BBB diffusion were monitored using these BF2 formazanate dyes in the NIR-II region. In murine glioblastoma models, these dyes can differentiate tumors from normal brain tissues. We anticipate that this new type of small molecule will find potential applications in creating probes and drugs relevant to theranostic for brain pathologies.
- 13 December 2022
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 144 (51) , 23668-23676
Photostable Small-Molecule NIR-II Fluorescent Scaffolds that Cross the Blood–Brain Barrier for Noninvasive Brain Imaging
The second near-infrared (NIR-II, 1000–1700 nm) fluorescent probes have significant advantages over visible or NIR-I (600–900 nm) imaging for both depth of penetration and level of resolution. Since the blood-brain barrier (BBB) prevents most molecules from entering the central nervous system, NIR-II dyes with large molecular frameworks have limited applications for brain imaging. In this work, we developed a series of boron difluoride (BF2) formazanate NIR-II dyes which had tunable photophysical properties, ultrahigh photostability, excellent biological stability, and strong brightness. Modulation of the aniline moiety of BF2 formazanate dyes significantly enhances their abilities to cross the BBB for noninvasive brain imaging. Furthermore, the intact mouse brain imaging and dynamic BBB diffusion were monitored using these BF2 formazanate dyes in the NIR-II region. In murine glioblastoma models, these dyes can differentiate tumors from normal brain tissues. We anticipate that this new type of small molecule will find potential applications in creating probes and drugs relevant to theranostic for brain pathologies.
- Open Access
- 12 October 2022
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 13 (42) , 12540-12549
Xanthone-based solvatochromic fluorophores for quantifying micropolarity of protein aggregates
Using a single atom substitution approach, we have developed a series of solvatochromic fluorophores that respond solely to polarity. The utility of these fluorophores is demonstrated by quantifying the polarity of misfolded and aggregated proteins.
- 12 October 2022
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 13 (42) , 12540-12549
Open AccessXanthone-based solvatochromic fluorophores for quantifying micropolarity of protein aggregates
Using a single atom substitution approach, we have developed a series of solvatochromic fluorophores that respond solely to polarity. The utility of these fluorophores is demonstrated by quantifying the polarity of misfolded and aggregated proteins.
- Open Access
- 25 June 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (26) , eabf2051
Harnessing the power of antibodies to fight bone metastasis
Precision modification of antibodies with bone-targeting moieties unleashes their potential for the treatment of bone metastases.
- 25 June 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (26) , eabf2051
Open AccessHarnessing the power of antibodies to fight bone metastasis
Precision modification of antibodies with bone-targeting moieties unleashes their potential for the treatment of bone metastases.
- 10 April 2018
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 20 (8) , 2213-2215
Studies toward the Synthesis of Iriomoteolide-2a: Construction of the C(6)–C(28) Fragment
The synthesis of an appropriately functionalized advanced C(6–28) fragment (3) of the marine macrolide iriomoteolide-2a (1) has been achieved in a highly efficient manner. The C(6)–C(18) fragment of 1 is prepared via a radical cyclization of a vinyl ether intermediate and palladium-promoted hydrostannylation/iodination. Paterson aldol reaction and Peterson olefination are used to construct the C(19)–C(28) fragment. The union of the C(6)–C(18) and C(19)–C(28) fragments is accomplished via a Suzuki–Miyaura coupling reaction.
- 10 April 2018
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 20 (8) , 2213-2215
Studies toward the Synthesis of Iriomoteolide-2a: Construction of the C(6)–C(28) Fragment
The synthesis of an appropriately functionalized advanced C(6–28) fragment (3) of the marine macrolide iriomoteolide-2a (1) has been achieved in a highly efficient manner. The C(6)–C(18) fragment of 1 is prepared via a radical cyclization of a vinyl ether intermediate and palladium-promoted hydrostannylation/iodination. Paterson aldol reaction and Peterson olefination are used to construct the C(19)–C(28) fragment. The union of the C(6)–C(18) and C(19)–C(28) fragments is accomplished via a Suzuki–Miyaura coupling reaction.
- 1 June 2011
- Published by Elsevier in Orthopaedics and Trauma
- Vol. 25 (3) , 181-189
(iv) Cervical spondylotic myelopathy: a brief review of its pathophysiology, presentation, assessment, natural history and management
- 1 June 2011
- Published by Elsevier in Orthopaedics and Trauma
- Vol. 25 (3) , 181-189
(iv) Cervical spondylotic myelopathy: a brief review of its pathophysiology, presentation, assessment, natural history and management